Brand & Product Security

Articles

Trump anticipates that the executive order will help lower drug prices by 30% to 80%.

White House Introduces Most Favored Nation EO

Videos


In the final part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ senior director of DSCSA/serialization compliance services, discusses the obstacles in documenting and proving DSCSA compliance.

Serialization System SOPs

The financial decision is due to customer demand stemming from the reshoring of drug supply services.

Piramal Pharma to Invest $90 Million in US Site Expansions

The President plans to sign an executive order on Monday morning to enforce the trade clause.

President Trump Announces Most-Favored-Nation Policy for Pharma Prices


In the second part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ senior director of DSCSA/serialization compliance services, comments on stakeholders’ overall preparedness for complying with the latest enforcement deadlines.

Is the Industry Ready for the DSCSA?


In the first part of his Pharma Commerce video interview, Michael Rowe, Two Labs’ senior director of DSCSA/serialization compliance services, shares his overall thoughts on this year’s DMC.

Key Takeaways From the 2025 HDA Distribution Management Conference

A seminar shares key observations and learnings from the first round of direct price negotiations.

Asembia 2025: Understanding the Inflation Reduction Act

IQVIA’s Doug Long offers a lay of the land, including trends and developing issues that are shaping the current market. 

Asembia 2025: A General Landscape of the Pharmaceutical Industry

A session dives into the trends surrounding specialty drugs and therapies, along with providing an overview of the drug development landscape. 

Asembia 2025: The Specialty Pharma Pipeline

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Paul Levesque, CEO of Theratechnologies, describes the uneasiness behind regulatory complications. 

Legal & Regulatory